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Abstract
Background: Overweight (Ow) and obesity (Ob) influence blood pressure (BP) and left ventricular hypertrophy (LVH). It is
unclear whether the presence of metabolic syndrome (MetS) independently affects echocardiographic parameters in
hypertension.
Methods: 380 Ow/Ob essential hypertensive patients (age #65 years) presenting for referred BP control-related problems.
MetS was defined according to NCEP III/ATP with AHA modifications and LVH as LVM/h
2.7 $49.2 g/m
2.7 in males and
$46.7 g/m
2.7 in females. Treatment intensity score (TIS) was used to control for BP treatment as previously reported.
Results: Hypertensive patients with MetS had significantly higher BMI, systolic and mean BP, interventricular septum and
relative wall thickness and lower ejection fraction than those without MetS. LVM/h
2.7 was significantly higher in MetS
patients (59.14614.97 vs. 55.33614.69 g/m
2.7; p=0.022). Hypertensive patients with MetS had a 2.3-fold higher risk to have
LVH/h
2.7 after adjustment for age, SBP and TIS (OR 2.34; 95%CI 1.40–3.92; p=0.001), but MetS lost its independent
relationship with LVH when BMI was included in the model.
Conclusions: In Ow/Ob hypertensive patients MetS maintains its role of risk factor for LVH independently of age, SBP, and
TIS, resulting in a useful predictor of target organ damage in clinical practice. However, MetS loses its independent
relationship when BMI is taken into account, suggesting that the effects on MetS on LV parameters are mainly driven by the
degree of adiposity.
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Introduction
Obesity and obesity-related hypertension are rapidly increasing
worldwide together with their metabolic and cardiovascular
complications [1–3]. Left ventricular hypertrophy (LVH) is one
of the complications and is, in turn, an important risk factor for
myocardial infarction, heart failure, stroke, and cardiac sudden
death [4]. Blood pressure (BP) is the main determinant of the
hemodynamic workload for the left ventricle and, in turn, of left
ventricular mass (LVM) [5], although both hemodynamic and
non-hemodynamic factors are involved in the complex pathogen-
esis of LVH [6,7]. Obesity represents both a hemodynamic and
non-hemodynamic risk factor for LVH, even independently of BP
[7], and increasing body mass index (BMI), the most studied and
commonly used in practice index of adiposity, is by itself associated
with increasing cardiovascular and metabolic complications [1].
The metabolic syndrome (MetS), an insulin-resistant state
characterized by a cluster of cardiovascular risk factors, is
increasing in prevalence in developed and developing countries
too [8]. MetS is strongly associated with increased risk for both
type 2 diabetes and cardiovascular disease [9–11], although
criticisms have been raised about its role as independent risk factor
beyond the contribution of each of its components [12–14].
The main aim of this study was to evaluate whether MetS is an
independent risk factor for LVH in overweight/obese (Ow/Ob),
non-elderly, hypertensive patients. In particular, we aimed to
verify whether the relationship between MetS and LVH is
independent from BMI.
Methods
In this cross-sectional study, 436 consecutive patients referred to
our Hypertension Centre from January 2006 to April 2009
because of BP-control-related problems were evaluated. Inclusion
criteria were: a) essential untreated hypertension or stable anti-
hypertensive drug treatment during the previous 6 months; b)
Ow/Ob (BMI$25 kg/m
2). When clinically indicated [15], a
complete study to exclude secondary hypertension was performed.
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related overlapping and confounding factors such as increasing
prevalence in vascular and renal damage), low compliance to anti-
hypertensive drug therapy as investigated by Morisky Medical
Adherence Scale (MMAS) [16] to evaluate adherence levels,
severe renal damage defined as glomerular filtration rate (eGFR)
,30 ml/min, diabetes mellitus type 1, any race other than white
Caucasian, heart failure NYHA III or IV or left ventricular
ejection fraction (LVEF) ,50%, liver failure, cancer or other
systemic severe diseases. Patients with incomplete clinical or
echocardiographic data were also excluded. After this selection,
380 patients met the inclusion and exclusion criteria and were
enrolled in the study. Each participant gave informed written
consent and all clinical investigations have been conducted
according to the principles expressed in the Declaration of
Helsinki. This observational study was approved by local
institutional ethics committee (Comitato Etico, Azienda Ospedali
Riuniti, Ancona).
Measurements
Body weight and height were measured on a standard beam
balance scale with an attached ruler. Body weight was measured to
the nearest 0.1 kg, and height was measured to the nearest 1 cm.
Waist circumference was measured in orthostatism with the
patient standing relaxed, arms freely hanging at each side, and feet
close together by using a flexible plastic tape to the nearest 1 cm
according and classified to NECP ATP III [17].
BP was measured following indications of the ESH-ESC
guidelines [15] using validated mercury-free digital sphygmoma-
nometers (A&D, UM-101) with appropriate cuff size. The average
of three consecutive measurements was used for the analysis.
Controlled BP was defined as systolic BP (SBP) ,140 mmHg and
diastolic BP (DBP) ,90 mmHg. When type 2 diabetes was
present, values ,130/80 mmHg were used as cut-offs to define
controlled BP. In a subset of patients (n=184), when clinically
indicated following ESH guidelines [15], 24-hour ambulatory
blood pressure measurements (Spacelabs, 90207) were also taken
and analyzed.
Blood samples for plasma fasting glucose, total and HDL
cholesterol, triglycerides, and creatinine as well as first morning
urine specimens to determine albumin creatinine ratio (ACR) were
obtained. All analyses were performed in the certified (ISO
9001:2000) University Hospital Central Laboratory. Microalbu-
minuria was defined as ACR $22 mg/g of urinary creatinine in
men and $31 mg/g in women [15]. Glomerular filtration rate
(eGFR) was estimated by using the Modification of Diet in Renal
Disease Study equation [18].
MetS was defined according to NCEP/ATP III classification as
modified by the AHA [17], when, in addition to high BP (which
was an inclusion criteria and therefore a common feature of all
enrolled patients), two or more of the following criteria were also
present: waist $102 cm in men and $88 cm in women, HDL
#40 mg/dl in men and #50 mg/dl in women, triglycerides
$150 mg/dl, and fasting glucose $100 mg/dl (or diagnosis of
type 2 diabetes).
Anti-hypertensive treatment
To allow for comparability of drug regimens across patients
taking many different medications, a treatment intensity score
(TIS) was calculated. As previously reported [19], the recorded
daily dose taken by the patient was divided by the maximum
recommended daily dose to obtain a proportional dose for that
medication, called intensity. For completeness, dual-class drugs
were separated into their components and intensities were
calculated separately for each of the chemical compounds.
Maximum recommended daily doses set by the Italian national
agency for drugs (Agenzia Italiana del Farmaco, AIFA) at the time
of each single visit were used for calculations. The sum of all the
different values was recorded as TIS.
Echocardiography
Left ventricular dimensions were measured by echocardiogra-
phy (ATL HDI 5000, Philips) following the American Society of
Echocardiography recommendations [20]. For each patient the
following measurements were taken: end-diastolic and end-systolic
interventricular septum thickness (IVSD and IVSS, respectively),
posterior wall thickness (PWD and PWS, respectively), and left
ventricular diameters (LVDD and LVDS, respectively); left atrial
diameter (LAD). LVM was calculated (M-mode tracings under
two-dimensional control, left parasternal short axis view, mean of
three cardiac cycles) by using the Devereux’s formula [21] and
indexed by either body surface area (LVMi) or height
2.7 (LVM/
h
2.7) [22]. Because all of the patients were overweight or obese,
LVH was defined on the basis of the LVH/h
2.7, using $49.2 g/
m
2.7 in men and $46.7 g/m
2.7 in women as partition values [23].
Myocardial relative wall thickness (RWT) was also calculated and
a RWT$0.45 defined concentric remodeling (CR) [24]. LVEF
was calculated as (LV end-diastolic area – LV end-systolic area)/
LV end-diastolic area (two dimensional apical four-chambers view,
mean of three cardiac cycles) [25].
Statistical Analysis
The study was planned to have a sample size of $120 subjects
in each group. The sample size was calculated on averages and
standard deviations of previous publications exploring similar
issues [26]. This study had a .80% power to detect a LVM/h
2.7
difference $2.5 g/m
2.7 between patients with or without MetS
(with a=0.05), assuming a standard deviation of 11 g/m
2.7.
Differences between patients with or without MetS were evaluated
by using analysis of variance (ANOVA) adjusted for age and sex
for continuous variables and the x
2 test for categorical variables.
Logistic regression analysis was used to create adjusted models
including independent variables associated with LVH/h
2.7. SPSS
13.0 for Windows (SPSS Inc. Chicago, IL, USA) was used for all
the statistical analyses. A value of p,0.05 was considered as
statistically significant.
Results
Clinical characteristics of the 380 studied patients, adjusted for
age and sex, are shown in Table 1. Prevalence of MetS in our
sample was 65% despite age ,65 years old. Three hundred thirty
seven patients (88.7%) were on stable treatment for at least 6
months whereas forty three (11.3%) were untreated. 86 patients
(23.9%) had diabetes mellitus type 2. Among treated patients, no
differences were found in TIS and in prevalence of each single
anti-hypertensive drug class between patients with and without
MetS. Among many expected differences, MetS patients had
significantly higher BMI, eGFR and ACR.
Echocardiographic parameters, adjusted for age and sex, are
shown in Table 2. LVMi was not significantly different between
Ow/Ob hypertensive patients with or without MetS, whereas
those with MetS had significantly higher LVM/h
2.7 than those
without. MetS patients had also significantly higher RWT and
lower LVEF.
In univariate analysis, MetS was strictly related to the presence
of cardiac hypertrophy as defined by LVH/h
2.7 and CR. Patients
with MetS had a 2.8-fold higher relative risk to have CR (OR 2.81
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have LVH/h
2.7 (OR 2.28; 95% CI 1.43–3.62; p,0.001). When
MetS was present in Ow/Ob hypertensive patients, prevalence of
CR raised from 8.3% to 20.2% while prevalence of LVH/h
2.7
increased from 61.7% to 78.5% (see IC and p values above).
Logistic regression models were used to test the independent
role of risk factors for LVH/h
2.7. In the first model including each
single criteria of MetS (SBP, DBP, waist, fasting glucose, HDL
cholesterol and tryglicerides along with diagnosis of diabetes or
dyslipidemia), only SBP resulted independently associated with
LVH/h
2.7 (table 3, model 1). When BMI was introduced in the
model (instead of waist) both SBP and BMI resulted as
independent risk factors (table 3, model 2). In another model
including SBP, MetS, therapy (as described by TIS) and BMI all of
them except MetS resulted as independent risk factors for LVH/
h
2.7 (Table 4, model 1). However, once BMI was excluded from
the model, MetS resulted significantly associated to LVH/h
2.7
(Table 4, model 2). The inclusion in the latter models of
dichotomous variables representing current active treatment with
common anti-hypertensive drug classes (i.e. ACE-I/ARBs, b-
blockers, calcium channel blockers) did not affect the results. In the
subgroup of patients (n=184, 48%) in which 24-hour ambulatory
blood pressure measurements were available, the use of 24-hour
SBP instead of ‘‘office’’ SBP confirmed the results, and the overall
fit of the models actually improved (Nagelkerke square 0.32,
table 4, model 3 and 4).
Regarding gender, both in men and in women MetS is
associated with a similar increase in LVH/h
2.7 prevalence (from
60% to 78% in men and from 68% to 79% in women) and with a
similar relative risk for LVH/h
2.7 (OR 2.1 for women and 2.4 for
Table 1. General characteristics of the population.
Variable
Ow/Ob hypertensives
(n=380)
No MetS
(n=133)
MetS
(n=247) p
Sex (M/F) 251/129 85/48 166/81 .52
Age (yrs) 52.469.1 52.1 (0.8) 52.9 (0.6) .42
Hypertension diagnosis (yrs) 5.467.1 5.7 (0.7) 5.5 (0.7) .82
Anti-hypertensive therapy (%)
{ 88.7 88.7 88.6 .93
Dyslipidemia (%)
{ 77.1 63.1 84.6 ,.001
Diabetes (%)
{ 23.9 0.9 32.0 ,.001
Lipid-lowering therapy (%)
{ 15.8 0.0 24.3 ,.001
Hypoglycemic therapy (%)
{ 9.7 2.2 13.8 ,.001
Smoking habit (%)
{ 52.1 48.1 54.2 .25
BMI (kg/m
2) 31.9765.41 30.9 (0.5) 33.3 (0.4) ,.001
Waist (cm) 107.82613.36 102.9 (1.2) 109.6 (1.1) .001
SBP (mmHg) 150.24619.46 145.6 (1.7) 152.2 (1.3) .002
DBP (mmHg) 90.92612.63 89.1 (1.1) 91.5 (0.8) .08
MBP (mmHg) 110.69613.08 137.6 (1.5) 142.3 (1.1) .014
Fasting glucose (mg/dl) 106.98635.85 98.1 (3.1) 126.6 (2.3) .007
Total cholesterol (mg/dl) 205.80647.10 204.1 (4.3) 207.2 (3.7) .59
HDL (mg/dl) 43.93611.23 51.0 (0.9) 42.6 (0.8) ,.001
Triglycerides (mg/dl) 173.866146.93 110.9 (12.5) 212.0 (10.9) ,.001
LDL (mg/dl) 127.07639.73 131.2 (3.6) 122.2 (3.1) .06
GFR (ml/min) 103.63630.45 97.9 (2.6) 105.4 (1.9) .023
ACR (mg/g creat) 57.606203.09 17.2 (26.7) 67.2 (19.7) .035
TIS 1.4961.05 1.45 (0.10) 1.56 (0.07) .36
Results of analysis of variance (ANOVA);
{results of x
2 test. Data are mean 6 SD or absolute numbers. Data, adjusted for age and sex, are expressed as mean (standard error). Fasting glucose is adjusted for age,
sex and hypoglycemic therapy. Total cholesterol, HDL, triglycerides and LDL are adjusted for age, sex and lipid-lowering therapy.
doi:10.1371/journal.pone.0016630.t001
Table 2. Echocardiographic characteristics of the population.
Variable
Ow/Ob
hypertensives
n=380
No MetS
n=133
MetS
n=247 p
IVSTD (mm) 10.5161.56 10.1061.39 10.4961.63 .019
IVSTS (mm) 15.0162.25 14.7762.38 14.8862.18 .702
PWTD (mm) 9.8861.40 9.5661.36 9.8261.41 .079
PWTS (mm) 15.5062.14 15.4362.01 15.3262.21 .703
LVIDD (mm) 52.0265.51 51.1765.03 51.4765.76 .617
LVIDS (mm) 33.8065.94 31.8765.60 33.0465.94 .069
LAD (mm) 40.2265.58 39.5566.07 39.8665.30 .616
LVMi (g/m
2) 116.19630.16 111.17630.19 113.28630.14 .506
LVM/h
2.7 (g/m
2.7) 58.28614.99 55.33614.69 59.14614.97 .022
RWT .396.06 .386.05 .406.06 .024
LVEF (%) 65.74610.11 67.9969.97 65.51610.07 .028
Results of analysis of variance (ANOVA). Data are mean 6 SD; data adjusted for
age and sex, are expressed as mean (standard error).
doi:10.1371/journal.pone.0016630.t002
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planned to test gender-dependent differences in MetS and LVH
relationship. Moreover, different partition values for LVH were
used in men and women.
Left ventricles without both CR and LVH/h
2.7 were defined as
‘‘normal’’, LV with CR in the absence of LVH/h
2.7 were defined
as having LV ‘‘concentric remodeling’’, LV with LVH/h
2.7 but
without CR were defined as having ‘‘eccentric hypertrophy’’, and
LV with both CR and LVH/h
2.7 were defined as having
‘‘concentric hypertrophy’’. Their respective prevalences with or
without MetS are shown Figure 1. Distribution of these subtypes of
cardiac damage between patients with or without MetS were
significantly different (x
2 test, p,0.001), with MetS patients having
higher prevalence of CR, eccentric hypertrophy, and concentric
hypertrophy (Figure 1).
Discussion
Ow/Ob hypertensive patients often have high cardiovascular
risk and the presence of LVH and/or MetS further increase their
risk. It is unclear whether MetS is an independent risk factor for
LVH in these patients and the present study aimed at investigating
this issue. The main finding of our investigation was that in Ow/
Ob, non elderly, hypertensive patients MetS is not associated with
LVH/h
2.7 when BMI is taken into account.
The ‘‘surprising’’ finding that BMI is the driving factor behind
MetS-related LV increased mass was not totally unexpected but
has never been specifically tested before, especially in a context of
ow/ob non-elderly hypertensive patients.
We chose to investigate LVH as defined by LVM/h
2.7 cut-offs
because body surface area correction reduces variability due to
body size and gender [27] and underestimates LVM in the upper
range of the body surface area distribution [22]. Thus,
normalizing by height
2.7 seems to offer the most accurate
estimation of LVM and risk factors for pathologic changes in
heart structure in overweight and obese subjects [28]. Moreover,
even direct unadjusted measurements of cardiac remodeling such
as IVSTD and RWT, showed similar differences between patients
with and without MetS.
It has been previously demonstrated that in females MetS had a
greater impact on LVH and the effect of MetS was partly
independent from the effect of several determinants of LV mass
[29]. We found that both in men and women MetS was associated
with a similar increase in LVH/h
2.7 prevalence and a similar
relative risk for LVH/h
2.7. However, the study sample size was not
planned to test specific gender differences in MetS and LVH
relationship and therefore it is not possible to confirm a previous
report [29].
In our population, as well as in larger populations such as the one
of the PAMELA study [30], patients with MetS had significantly
higherBP.HigherSBP,particularlythroughincreasedcardiacload,
can partially explain the increased LVM found in MetS subjects.
However, in our logistic regression models, MetS maintained its
relationship with LVH independently of SBP, even if SBP was the
only variable independently correlated to LVH when all different
components of MetS were accounted for.
Table 3. Independent risk factors for LVH/h
2.7 assessed by
logistic regression models.
Variable Model 1 Model 2
OR 95% CI p OR 95% CI p
Waist 1.02 0.99 1.02 .099
SBP 1.03 1.01 1.06 .002 1.03 1.01 1.05 ,.001
DBP 1.01 0.97 1.03 .381 1.02 0.99 1.03 .193
Fasting glucose 1.01 0.99 1.03 .222 1.00 0.99 1.01 .953
HDL 0.97 0.94 1.00 .054 0.98 0.96 1.01 .165
Triglycerides 1.00 0.99 1.00 .938 1.00 0.99 1.00 .214
Diabetes 0.28 0.22 1.53 .276 1.01 0.44 2.32 .971
Dyslipidemia 0.77 0.42 1.91 .772 0.82 0.44 1.53 .538
BMI 1.22 1.13 1.31 ,.001
Model 1 included waist, SBP, DBP, fasting glucose, HDL cholesterol and
triglycerides along with diagnosis of diabetes or dyslipidemia as covariates.
Model 2 included all model 1 variables except waist, which was substituted by
BMI, as covariates. No adjustment for sex was applied because of the different
partition values for LVH/h
2.7 used for males and females.
doi:10.1371/journal.pone.0016630.t003
Table 4. Independent risk factors for LVH/h
2.7 assessed by logistic regression models.
Variable Model 1 Model 2
OR 95% CI p OR 95% CI p
SBP 1.02 1.00 1.03 .009 1.02 1.00 1.03 .010
MetS 1.68 0.97 2.92 .065 2.34 1.40 3.92 .001
TIS 1.36 1.02 1.80 .036 1.46 1.12 1.92 .006
BMI 1.19 1.10 1.28 ,.001
Variable Model 3 Model 4
OR 95% CI p OR 95% CI p
24-h SBP 1.06 1.03 1.09 .006 1.05 1.02 1.08 .001
MetS 2.74 0.96 6.99 .061 4.62 2.15 9.94 ,.001
TIS 1.77 1.14 2.63 .010 1.85 1.26 2.76 .002
BMI 1.18 1.06 1.33 ,.001
Model 1 included SBP, MetS, TIS and BMI as covariates. Model 2 included all model 1 variables except BMI as covariates. Model 3 and 4 are similar respectively to model
1 and 2 but with 24-hour SBP instead of ambulatory SBP. No adjustment for sex was applied because of the different partition values for LVH/h
2.7 used for males and
females.
doi:10.1371/journal.pone.0016630.t004
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and 5-fold higher ACR, indicating that in these hypertensive
patients the kidneys too showed signs of increased overload and
damage. Therefore in hypertensive patients the presence of MetS
associates with more severe organ damage and higher cardiovas-
cular risk.
However, it is still unclear if MetS, even across different
definitions, adds something more than the sum of each of its
components in predicting organ damage. In our study MetS was
not able to predict LVH independently of BMI, the most used,
widespread and clinically useful marker of increased adiposity.
Although waist, as a single component, was not an independent
determinant of LVH in our analysis, there is increasing evidence
that regional fat distribution (abdominal but even epicardial,
pericardial or mediastinal adipose tissue) could contribute to
cardiac remodeling and hypertrophy [31,32]. The effect of MetS
on the relationship among fat mass, fat distribution and LVM is
however still unclear. When the different components of MetS
were studied in logistic regression models along with BMI, only
SBP and BMI resulted in having an independent relationship with
LVH. Some authors reported that MetS is a risk factor for LVH
independently of BMI [26,33], and might play an important role
in cardiac restructure above BP and increased BMI. However,
several differences must be considered between the present study
and previous published papers. First, population, inclusion and
exclusion criteria, as well as criteria used to define MetS were
different. Our population excluded elderly and people with severe
reduction of eGFR to limit as much as possible confounding
factors, such as vascular damage and severe renal impairment.
Second, in both published papers [26,33], 65% and 55% of the
studied patients, respectively, were on pharmacological treatment
that was discontinued 2 weeks before enrollment. This approach
obviously led to a return of BP towards original levels without a
similar regression in LVM, an important confounding factor that
we think is often overlooked. This confounding factor is
particularly important when the population is mixed regarding
treatment and when a considerable percentage was not treated at
all, as in previous studies [26,33]. Studies with never treated
hypertensive patients are very rare but are source of very
important information [29]. In our study, we chose not to suspend
treatment and, on the contrary, we enrolled only untreated
patients or patients on stable anti-hypertensive therapy in order to
have the best possible ‘‘real’’ correspondence between obtained BP
measurements, LVM, and pharmacological treatment. Third, we
preferred to use different statistical methods (logistic regression
rather than multiple linear regression analysis with MetS as a
dummy variable). We believe that these differences in methods
overall improved the study and led to our results.
Our data are also supported, at least in part, by some previous
published investigations. For example, a recent paper by Tsioufis
et al. [34], demonstrated that MetS did not worsen hypertension-
induced restructuring of left ventricle and large arteries in
untreated hypertensive patients. Moreover, in their multiple linear
regression model, in which MetS was included as a dummy
variable together with age, sex, BMI, smoking, 24-h SBP and
DBP, only BMI, age, and 24-h SBP resulted independent
predictors of LVM/h
2.7 [34]. Indeed we performed a logistic
regression analysis using LVH/h
2.7 as the dependent variable,
similar predictors resulted also in the subgroup with 24-hour SBP
(table 4, model 3 and 4). Moreover, the significant difference and
relevance of SBP over DBP underlines the key importance of
volume-related BP increase, another characteristic of Ow/Ob
related hypertension.
Some limitations of this study must be taken into account. First,
our population is made exclusively of patients studied in a single
Hypertension Centre because of not completely controlled BP as
referred by their general practitioners. This selection ‘‘bias’’ can
explain the high prevalence of MetS (65%), diabetes (23.9%) and
dyslipidemia (77.1%) as well as the high BP levels despite active
pharmacological treatment in the vast majority of patients. It is
well known that in obese hypertensive patients it is very difficult to
reach BP control [8]. Thus, our study is relevant for an important
condition commonly found in ‘‘real life’’ medical practice. Due to
inclusion criteria, the mean BMI in our population is quite high
(31.97 kg/m
2) and that could, at least in part, explain the high
prevalence of eccentric hypertrophy. In fact it is known that the
eccentric pattern of remodeling and hypertrophy is the most
prevalent in obesity, being obesity a strong predictor of eccentric
LVH [35]. Moreover, increased cardiac workload because of not
completely controlled hypertension may explain the higher
prevalence of concentric hypertrophy in our sample as compared
to other populations, such as the one of the LIFE study [36]. It is
indeed well known that different patterns of LV remodeling can be
observed in obesity [37]. Second, although inclusion of TIS and
drug-class treatment as a dummy variable did not significantly
change the results, we were not able to take into account all the
details of all the different classes and subtypes of drugs assumed by
the patients, which in turn might have affected the results
obtained. However, this is a common limitation of many published
works when ‘‘real practice’’ patients are studied.
In conclusion, our finding suggests that the higher prevalence of
LVH and CR is strongly associated with higher BMI and SBP in
Ow/Ob hypertensive patients. Increased relative risk of LVH due
to the presence of MetS, once excluded age and BP, seems
mediated mainly by BMI (as an index of increased adiposity),
which works as both a hemodynamic and non-hemodynamic
factor [6,7]. Therefore if we consider increased adiposity as an
integral part of MetS, MetS is indeed an independent risk factor
Figure 1. Prevalence of concentric remodelling, eccentric and
concentric hypertrophy in Ow/Ob hypertensive patients.
doi:10.1371/journal.pone.0016630.g001
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Otherwise, because BMI is not formally a component of the
MetS definition we may conclude that MetS is not an independent
risk factor because its effects are mainly mediated by increased
BMI in hypertensive patients.
At the end, excessive, inappropriate adiposity, in the context of
hypertension, is the key factor further influencing left ventricular
mass and geometry.
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